Received Jan 15, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MMRV | MEASLES + MUMPS + RUBELLA + VARICELLA (PROQUAD) | MERCK & CO. INC. | UNK | Z011683 | — |
| VARCEL | VARICELLA (VARIVAX) | MERCK & CO. INC. | UNK | Z008873 | — |
No side effects or symptoms reported. No additional AE/ No PQC.; received VARIVAX and PROQUAD vaccines on the same day; This spontaneous report was received from a medical assistant and refers to a 12-month-old female patient. The patient's medical history was not reported. The patient's concurrent conditions were not reported. Concomitant therapies were not reported. On 14-Dec-2025, the patient received Varicella Virus Vaccine Live (Oka-Merck) (VARIVAX) injection (valid lot #Z008873, expiration date: 14-May-2027), 0.5 mL (strength, anatomical location, dose number, and route were not provided) and Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live (PROQUAD) injection (valid lot #Z011683, expiration date: 10-Jan-2027), 0.5 mL (strength, anatomical location, dose number, and route were not provided) on the same day in two separate injection sites (unspecified), both for prophylaxis (Overdose). The vaccines were reconstituted with sterile diluent solution for injection (lot # and expiration date were not provided). No side effects or symptoms reported. No additional adverse event (AE) (No adverse event). Follow-up information was received from the primary reporter on 12-JAN-2026. The patient's age was incorrect. Option to update the age to 12 months on her end was not appropriate. Therefore, the patient's age and age group were deleted.
Sterile Diluent